301 related articles for article (PubMed ID: 19498041)
1. Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.
Sykes DA; Dowling MR; Charlton SJ
Mol Pharmacol; 2009 Sep; 76(3):543-51. PubMed ID: 19498041
[TBL] [Abstract][Full Text] [Related]
2. An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.
Mistry R; Dowling MR; Challiss RA
Br J Pharmacol; 2005 Feb; 144(4):566-75. PubMed ID: 15655507
[TBL] [Abstract][Full Text] [Related]
3. Interactions of agonists with M2 and M4 muscarinic receptor subtypes mediating cyclic AMP inhibition.
McKinney M; Miller JH; Gibson VA; Nickelson L; Aksoy S
Mol Pharmacol; 1991 Dec; 40(6):1014-22. PubMed ID: 1722002
[TBL] [Abstract][Full Text] [Related]
4. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists.
Michal P; Lysíková M; Tucek S
Br J Pharmacol; 2001 Mar; 132(6):1217-28. PubMed ID: 11250872
[TBL] [Abstract][Full Text] [Related]
5. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
6. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
Ladner CJ; Lee JM
Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
[TBL] [Abstract][Full Text] [Related]
7. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
8. New insight into active muscarinic receptors with the novel radioagonist [³H]iperoxo.
Schrage R; Holze J; Klöckner J; Balkow A; Klause AS; Schmitz AL; De Amici M; Kostenis E; Tränkle C; Holzgrabe U; Mohr K
Biochem Pharmacol; 2014 Aug; 90(3):307-19. PubMed ID: 24863257
[TBL] [Abstract][Full Text] [Related]
9. Action of the muscarinic toxin MT7 on agonist-bound muscarinic M1 receptors.
Olianas MC; Adem A; Karlsson E; Onali P
Eur J Pharmacol; 2004 Mar; 487(1-3):65-72. PubMed ID: 15033377
[TBL] [Abstract][Full Text] [Related]
10. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor.
Frucht H; Jensen RT; Dexter D; Yang WL; Xiao Y
Clin Cancer Res; 1999 Sep; 5(9):2532-9. PubMed ID: 10499630
[TBL] [Abstract][Full Text] [Related]
11. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy.
Jakubík J; Janíčková H; El-Fakahany EE; Doležal V
Br J Pharmacol; 2011 Mar; 162(5):1029-44. PubMed ID: 20958290
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice.
Gautam D; Heard TS; Cui Y; Miller G; Bloodworth L; Wess J
Mol Pharmacol; 2004 Aug; 66(2):260-7. PubMed ID: 15266016
[TBL] [Abstract][Full Text] [Related]
13. FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors.
Ziegler N; Bätz J; Zabel U; Lohse MJ; Hoffmann C
Bioorg Med Chem; 2011 Feb; 19(3):1048-54. PubMed ID: 20716489
[TBL] [Abstract][Full Text] [Related]
14. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
[TBL] [Abstract][Full Text] [Related]
15. Differential effects on [35S]GTPgammaS binding using muscarinic agonists and antagonists in the gerbil brain.
Pilar-Cuéllar F; Paniagua MA; Mostany R; Pérez CC; Fernández-López A
J Chem Neuroanat; 2005 Oct; 30(2-3):119-28. PubMed ID: 16095872
[TBL] [Abstract][Full Text] [Related]
16. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
[TBL] [Abstract][Full Text] [Related]
17. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
Machová E; Jakubík J; El-Fakahany EE; Dolezal V
J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
[TBL] [Abstract][Full Text] [Related]
18. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium.
Ehlert FJ
Mol Pharmacol; 1985 Nov; 28(5):410-21. PubMed ID: 4058422
[TBL] [Abstract][Full Text] [Related]
19. Application of competition kinetics to investigate rat brain muscarinic receptors.
Schreiber G; Henis YI; Sokolovsky M
Isr J Med Sci; 1987; 23(1-2):36-43. PubMed ID: 3570744
[TBL] [Abstract][Full Text] [Related]
20. A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M3 muscarinic receptors in guinea pig ileum and transfected cells.
Ehlert FJ; Griffin MT; Sawyer GW; Bailon R
J Pharmacol Exp Ther; 1999 May; 289(2):981-92. PubMed ID: 10215678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
